An increase in the 20q13 copy number has been reported in a wide range of s
olid tumors including breast cancers. However, the biological significance
of this 20g13 gain has not yet been defined. We examined the 20q13 gain in
breast cancer cells by dual-color FISH using two different DNA probes speci
fic for the region of 20q13 and chromosome 20 centromere to investigate the
relationship between 20q13 gain and the clinicopathological features of br
east cancers. DNA measurement by LSC revealed DNA diploidy in 14 tumors and
DNA aneuploidy in 24 tumors. Although the modal number of chromosome 20 wa
s 2 in most of the tumors, the average fraction of cells with the modal chr
omosomal number was significantly different in the diploid and aneuploid tu
mors (p < 0.01). A gain in the 20q13 copy number was detected in 9 of 38 br
east cancers, 2 of which showed a high-level gain. The gain in 20q13 was as
sociated with negative expression for the progesterone receptor, but it was
not linked to estrogen receptor expression. A 20q13 gain tended to be seen
in DNA aneuploid and/or scirrhous carcinomas, but the increase in the 20q1
3 copy number did not affect either the nodal stare or the disease stage in
this series.